TLK117 is developed as a GSTP1-1 isoenzyme inhibitor to overcome GSTP1-1-mediated drug resistance in tumor cells; it attenuates bleomycin- and AdTGFβ-induced fibrosis, remodeling, α-SMA expression, caspase activation, FAS S-glutathionylation, and total protein S-glutathionylation when administered oropharyngeally after fibrosis is established.